Treatment of dystonia

被引:227
作者
Jankovic, Joseph [2 ]
机构
[1] Baylor Coll Med, Dept Neurol, Movement Disorders Clin, Houston, TX 77030 USA
[2] Baylor Coll Med, Parkinsons Dis Ctr, Houston, TX 77030 USA
关键词
D O I
10.1016/S1474-4422(06)70574-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Dystonia, defined as a neurological syndrome characterised. by involuntary, patterned, sustained, or repetitive muscle contractions of opposing muscles, causing twisting movements and abnormal postures, is one of the most disabling movement disorders. Although gene mutations and other causes are increasingly recognised, most patients have primary dystonia without a specific cause. Although pathogenesis-targeted treatment is still elusive, the currently available symptomatic treatment strategies are quite effective for some types of dystonia in relieving involuntary movements, correcting abnormal posture, preventing contractures, reducing pain, and improving function and quality of life. A small portion of patients have a known cause and respond to specific treatments, such as levodopa in dopa-responsive dystonia or drugs that prevent copper accumulation in Wilson's disease. Therapeutic options must be tailored to the needs of individual patients and include chemodenervation with botulinum toxin injections for patients with focal or segmental dystonia, and medical treatments or deep brain stimulation for patients with generalised dystonia.
引用
收藏
页码:864 / 872
页数:9
相关论文
共 82 条
[1]
A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes:: report of an EFNS/MDS-ES Task Force [J].
Albanese, A. ;
Barnes, M. P. ;
Bhatia, K. P. ;
Fernandez-Alvarez, E. ;
Filippini, G. ;
Gasser, T. ;
Krauss, J. K. ;
Newton, A. ;
Rektor, I. ;
Savoiardo, M. ;
Valls-Sole, J. .
EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 (05) :433-444
[2]
Myoclonus-dystonia syndrome:: ε-sarcoglycan mutations and phenotype [J].
Asmus, F ;
Zimprich, A ;
du Montcel, ST ;
Kabus, C ;
Deuschl, G ;
Kupsch, A ;
Ziemann, U ;
Castro, M ;
Kühn, AA ;
Strom, TM ;
Vidailhet, M ;
Bhatia, KP ;
Dürr, A ;
Wood, NW ;
Brice, A ;
Gasser, T .
ANNALS OF NEUROLOGY, 2002, 52 (04) :489-492
[3]
Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options [J].
Balash, Y ;
Giladi, N .
EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 (06) :361-370
[4]
Intrathecal baclofen for stiff-person syndrome: Life-threatening intermittent catheter leakage [J].
Bardutzky, J ;
Tronnier, V ;
Schwab, S ;
Meinck, HM .
NEUROLOGY, 2003, 60 (12) :1976-1978
[5]
What are the determinants of quality of life in people with cervical dystonia? [J].
Ben-Shlomo, Y ;
Camfield, L ;
Warner, T .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 72 (05) :608-614
[6]
A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia [J].
Benecke, R ;
Jost, WH ;
Kanovsky, P ;
Ruzicka, E ;
Comes, G ;
Grafe, S .
NEUROLOGY, 2005, 64 (11) :1949-1951
[7]
Morphine in tardive and idiopathic dystonia [J].
Berg, D ;
Becker, G ;
Naumann, M ;
Reiners, K .
JOURNAL OF NEURAL TRANSMISSION, 2001, 108 (8-9) :1035-1041
[8]
Bertrand C M, 1988, Adv Neurol, V50, P637
[9]
TORSION DYSTONIA - A DOUBLE-BLIND, PROSPECTIVE TRIAL OF HIGH-DOSAGE TRIHEXYPHENIDYL [J].
BURKE, RE ;
FAHN, S ;
MARSDEN, CD .
NEUROLOGY, 1986, 36 (02) :160-164
[10]
Effect of sensory discrimination training on structure and function in patients with focal hand dystonia: A case series [J].
Byl, NN ;
Nagajaran, S ;
McKenzie, L .
ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 2003, 84 (10) :1505-1514